Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal
The Food and Drug Administration (FDA) is announcing the renewal of the Cardiovascular and Renal Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Cardiovascular and Renal Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the August 27, 2028, expiration date.
Related coverage
- Takes of Marine Mammals Incidental to Specified Activities; Taking Marine Mammals Incidental to the City and Borough of Juneau's Seawalk Extension Project, Juneau, Alaska
- Colorado Underground Injection Control (UIC) Program; Class VI Primacy
- Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
- Notice of Agency Determination on Waiver With Respect to Land; Indianapolis Downtown Heliport, Indianapolis, Indiana
- Magnuson-Stevens Fishery Conservation and Management Act Provisions; Fisheries of the Northeastern United States; Framework Adjustment 7 to the Atlantic Spiny Dogfish Fishery Management Plan
- Magnuson-Stevens Act Provisions; Fisheries off West Coast States; Pacific Coast Groundfish Fishery; Pacific Coast Groundfish Fishery Management Plan; Fixed Gear Marking and Entanglement Risk Reduction